Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00183807
Status:
TERMINATED
Last Update Posted:
2014-05-22
First Post:
2005-09-09
Brief Title:
A Study of Irinotecan Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
A Phase II Study of Irinotecan Camptosar Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
Status:
TERMINATED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Insufficient Accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is for patients with cancer of the esophagus This study uses the drugs irinotecan cisplatin and celecoxib Irinotecan also known as CPT-11 was recently approved by the US Food and Drug Administration FDA for use in colon cancer but has not been approved by the FDA for use in the treatment of cancers of the esophagus Cisplatin is a drug that is commonly used to treat patients with cancer of the esophagus We are combining these two chemotherapy drugs with a drug called Celebrex Celebrex also called Celecoxib is an oral medication that is approved by the FDA for pain in the treatment of arthritis There is some information to suggest that this drug may have anti-cancer activity In prior studies combining irinotecan and cisplatin tumors of the esophagus have been shown to shrink We are adding Celebrex to these drugs to see if it makes the drugs work better to shrink cancer or cause fewer side effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None